# US 2010/0168432 A1 · Process for the Preparation of Montelukast

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168432 A1
- Document ID: US20100168432A1
- Status: Published application
- Kind: A1
- Application number: 12/083,487
- Filed: 2006-06-30
- Published: 2010-07-01
- Earliest claimed: 2005-07-05
- Assignees: Matrix Laboratories Limited
- Inventors: Chava Satyanarayana; Gorantla Seeta Ramanjaneyulu; Indukuri Venkata Sunil Kumar
- Web page: https://patentgrep.com/patent/US20100168432A1

## CPC

- C07D 215/18: Halogen atoms or nitro radicals
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a process for the preparation of Montelukast or a salt thereof comprises, i) condensing Methyl-2-[3-[3-(2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-chloro propyljbenzoate obtained above with 1-(mercaptomethyl)cyclopropane acetic acid in presence of alkali carbonates such as Cesium Carbonate, followed by salification with organic amine ii) neutralizing the organic amine salt as obtained above with organic/inorganic acid followed by reaction with methylmagnesium chloride in the presence of Cerium Chloride followed by treatment with organic base yields montelukast amine salt iii) converting the montelukast amine salt to Montelukast Free acid iv) saltification of Montelukast free acid with Sodium hydroxide affords Montelukast Sodium.

## Claims

### Claim 1

A process for the preparation of Montelukast or a salt thereof, comprising steps:
i. Condensing Methyl-2-[3-[3-(2-(7-cloroquinolin-2-yl)ethenyl]phenyl]-3-chloro propyl]benzoate with 1-(mercaptomethyl)cyclopropane acetic acid followed by saltification with organic amine
ii. Neutralizing the amine salt obtained above with acetic acid followed by reaction with methylmagnesium chloride in the presence of anhydrous cerium chloride and isolating the product as montelukast amine salt
iii. Converting the montelukast amine salt obtained above to Montelukast Free acid.
iv. Saltification of Montelukast free acid with Sodium hydroxide affords Montelukast Sodium.

### Claim 2 (depends on 1)

The process as claimed in claim 1, wherein the condensation reaction of Methyl 2-[(3S)-[3-[2E)-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]benzoate with 1-(mercapto methyl)cyclopropane acetic acid is carried out in the presence of alkali carbonates

### Claim 3 (depends on 2)

The process as claimed in claim 2, wherein the alkali carbonate is Cesium Carbonate

### Claim 4 (depends on 2)

The process as claimed in claim 2, wherein the condensation reaction of Methyl 2-[(3S)-[3-[(2E)-(7-chloroquinolin-2yl)ethenyl)phenyl]-3-chloropropyl]benzoate with 1-(mercaptomethyl)cyclopropane acetic acid is carried out at a temperature between room temperature and about 100° C., most preferable at 40° C.-60° C.

### Claim 5 (depends on 2)

The process as claimed in claim 2, wherein the condensed product is isolated as amine salts selecting from dicyclohexylamine salt, cyclohexylethyl amine salt and α-methyl benzyl amine salt.

### Claim 6 (depends on 1)

The process as claimed in claim 1, wherein montelukast amine slat is prepared by
i. Contacting the residue obtained after reaction with methyl magnesium chloride with organic amine in ethanol and
ii. Precipitating the amine salt by adding diisopropyl ether

### Claim 7 (depends on 1)

The process as claimed in claim 1, wherein the montelukast free acid is isolated by neutralizing the montelukast amine salt

### Claim 8 (depends on 1)

The process as claimed in claim 1, wherein the montelukast sodium is prepared by
i. treating the montelukast free acid with sodium hydroxide in a suitable organic solvent
ii. concentrating the reaction mass after salt formation
iii. isolating the montelukast sodium in n-Heptane

### Claim 9 (depends on 9)

The process as claimed in claim 9, wherein sodium hydroxide is ethanolic sodium hydroxide

### Claim 10 (depends on 9)

The process as claimed in claim 9, wherein suitable organic solvent is selected from Diisopropylether, Methyl tert butyl ether, acetone, Ethylacetate, Toluene, Isopropylacetate, IPA or mixture thereof

### Claim 11

A process for the preparation of Montelukast or a salt thereof, comprising steps:
i. Reacting Methyl-2-[3-[3-(2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropyl]benzoate with methylmagnesium chloride in the presence of Cerium Chloride followed by treatment with organic amine yields amine salts
ii. Neutralizing the organic amine salt as obtained above with organic/inorganic acid followed by condensation with 1-(mercaptomethyl)cyclopropane acetic acid in presence of alkali carbonates such as Cesium Carbonate, followed by saltification with organic amine gives montelukast amine salts
iii. Converting the montelukast amine salt to Montelukast Free acid.
iv. Saltification of Montelukast free acid with Sodium hydroxide affords Montelukast Sodium

### Claim 12 (depends on 12)

The process as claimed in claim 12, wherein the alkali carbonate is Cesium Carbonate

### Claim 13 (depends on 12)

The process as claimed in claim 12, wherein th Cesium carbonate is used in a molar ratio in a range of 1.5 and 4.5 moles per mole of preparation of 2-[2-[3S-[3-[(2E)-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-chloropropyl]phenyl]-2-propanol

### Claim 14

2-[1-[1(R)-[3-[2-(7-Chloroquinolin-2yl)ethenyl)phenyl]-3-[2-(methoxycarbonyl)phenyl]propyl sulfanyl methyl]cyclopropyl]acetic acid α-methyl benzyl amine salt characterized by FTIR spectrum as shown in FIG. 1

### Claim 15

2-[1-[1(R)-[3-[2-(7-Chloroquinolin-2yl)ethenyl)phenyl]-3-[2-(methoxycarbonyl)phenyl]propyl sulfanyl methyl]cyclopropyl]acetic acid (S)-cyclohexyl ethyl amine salt characterized by FTIR spectrum as shown in FIG. 2.

### Claim 16

2-[1-[1(R)-[3-[2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methyl ethyl)phenyl]propyl sulfanyl methyl]cyclopropyl acetic acid (S)-cyclohexyl ethyl amine salt characterized by FTIR spectrum as shown in FIG. 3
